0591 Improving Efficiency & Patient Outcomes Using Longitudinal Monitoring via a HSAT with Hypoglossal Nerve Stimulation

Ruchir Patel,Stacey Gunn,Stephanie Messner,Haley Rodriguez,Erica Casselman,Amir Reuveny,Chelsie Rohrscheib
DOI: https://doi.org/10.1093/sleep/zsae067.0591
IF: 6.313
2024-04-20
SLEEP
Abstract:Abstract Introduction Hypoglossal Nerve Stimulation (HGNS) is an increasingly prevalent treatment for moderate-severe obstructive sleep apnea (OSA). HGNS therapy requires titration to identify the optimal stimulation parameters for patient comfort and OSA improvement. The recommended post-activation care protocol is long, typically taking 90-120 days to complete. The purpose of this study was to evaluate an optimized protocol utilizing a home sleep apnea test (HSAT) capable of long-term longitudinal monitoring to frequently assess treatment efficacy as stimulation amplitude adjustments were being made. Methods The study included 30 adults undergoing titration of an HGNS implant at a Sleep Clinic in Arizona, USA from January-October 2023. The revised protocol: The device was activated 3-weeks post-op and the stimulation amplitude was increased by 0.1V every 4 days following device activation. Patients were advised to test their sleep with a HSAT for 1 night on the 2nd night after every amplitude increase to minimize the risk of “1st night effect” after the initial amplitude increase. Follow-up visits were scheduled every 2 weeks post-activation, where the HSAT data was reviewed. Apnea/Hypopnea Index (AHI) and SPO2 were used to evaluate OSA severity. An in-lab titrations study was conducted 10-12 weeks post-activation if the patient was asymptomatic and adherent, and the HSAT showed significant improvement in OSA parameters. Results The updated care protocol took an average of 63.76 (SD 41.14) days from activation to completion 86.6% (n=26) of patients completed the program in < 90 days and 60% (n=18) completed the program in ≤60 days. The mean percent reduction in AHI was 68.09% (SD 21.89; mean -15.21 AHI). The mean increase in minimum SPO2 was 4.31% (SD 5.11). Conclusion A new HGNS titration protocol that included frequent testing with a HSAT allowed for objective, longitudinal assessment of the effectiveness of each amplitude/output adjustment. Monitoring OSA parameters minimized over-titration of the device amplitude, improving patient comfort, and allowed for earlier identification of the need to try a different electrode configuration if the AHI was not improving. This study demonstrated that a shorter program length was possible while still maintaining good treatment efficacy. Support (if any) Employees of Wesper contributed to the data analysis.
neurosciences,clinical neurology
What problem does this paper attempt to address?
The problem that this paper attempts to solve is to evaluate the safety and adverse events (AE) of hypoglossal nerve stimulation (HNS) in the treatment of obstructive sleep apnea (OSA). Specifically, the study aims to systematically review the published evidence to assess the adverse events and complications that occur during the treatment of OSA with HNS therapy, thereby providing a comprehensive safety assessment. ### Main problems of the paper: 1. **Evaluating the safety of HNS therapy**: By systematically reviewing published studies, assess the adverse events and complications during the treatment of OSA with HNS therapy. 2. **Analyzing the types and frequencies of adverse events**: Record and analyze in detail the adverse events related to surgery, devices, and treatment, including mortality, device removal rate, surgical revision rate, and treatment - related side effects. 3. **Making improvement suggestions**: Based on the research results, make suggestions for improving the adverse event reporting framework to ensure the comparability of results. ### Research methods: - **Literature search**: Systematically searched for relevant randomized controlled trials and observational studies from the MEDLINE, Cochrane, and Web of Science databases. - **Risk assessment**: Used the ROBINS - I tool to assess the risk of bias in the included studies. - **Data analysis**: Conducted a pooled analysis of adverse event data from 2,095 patients, including mortality, device removal rate, surgical revision rate, and treatment - related side effects. ### Main findings: - **Overall good safety**: The mortality rate of HNS therapy was 0.01%, the device removal rate was 0.03%, and the surgical revision rate was 0.08%. - **Major adverse events**: The most common adverse events were transient stimulation - related discomfort (0.08%) and tongue abrasion (0.07%). - **Reporting heterogeneity**: There was significant heterogeneity in the classification and level of detail of adverse event reporting. ### Conclusions: - **Good safety**: HNS therapy has good patient safety in the treatment of OSA, and adverse events mainly occur during the device implantation and treatment adaptation periods. - **Need for a standardized reporting framework**: To ensure the comparability of results, a standardized HNS outcome reporting framework, including the reporting of adverse events and side effects, needs to be implemented. This paper provides important evidence for the safety of HNS therapy through systematic review and analysis, and makes suggestions for improving adverse event reporting, which is helpful for improving the reliability and comparability of future studies.